FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

The FDA has approved a significant new treatment for pancreatic cancer, Revolution Medicines’ daraxonrasib, which has shown to nearly double average survival times in clinical trials. This breakthrough represents a major step forward in the fight against one of the most lethal forms of cancer. With survival rates for pancreatic cancer historically low, this drug could offer new hope for patients and their families. The approval signifies a major advancement in cancer treatment, potentially setting a new standard of care.